2 results
Approved WMOWill not start
The purpose of this first-in-human (FIH) study is to assess the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of subcutaneous (SC) VIS171 in healthy participants (single ascending dose [SAD] - Part A) as well as in…
Approved WMOPending
Primary objective: evaluate the performance of zirconium Zr 89 crefmirlimab berdoxam PET-CT for predicting patient response to immunotherapy. Secondary objectives: - evaluate the performance of zirconium Zr 89 crefmirlimab berdoxam PET-CT for…